Kwality Pharmaceuticals Peer Comparison

Kwality Pharmaceuticals Ltd. stands out in terms of revenue growth and valuation attractiveness compared to its peers. While it shows strong growth metrics, its profitability and debt levels are competitive, with several peers showing either overvaluation or financial stress. As a result, Kwality Pharmaceuticals presents a favorable investment opportunity in the current pharmaceutical landscape.

• • Kwality Pharmaceuticals shows the highest revenue growth YoY at 22.36% and a competitive PEG ratio of 0.67.
• • Dr. Reddy's Laboratories leads in profitability metrics with the highest ROE (21.76%) and ROCE (26.86%).
• • Divi's Laboratories is marked as financially weak due to negative revenue growth over 3 years and high valuation ratios.

• • Dr. Reddy's Laboratories Ltd.: Highest ROE and ROCE showing strong profitability.
• • Kwality Pharmaceuticals Ltd.: Highest revenue growth YoY and competitive valuation metrics.
• • Cipla Ltd.: Strong profitability with low PE ratio and solid growth.